Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas

NCT05832827 is registered in ClinicalTrials.gov with National Cancer Center, Japan as lead sponsor.

NCT NCT05832827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05832827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas
Lead sponsor
National Cancer Center, Japan
Phase
Phase 2
Overall status
Recruiting
Start date
September 4, 2023
Completion date
June 30, 2028
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

untreated advanced or recurrent thymic carcinomas